BioBehavioral Diagnostics Company Patents
BioBehavioral Diagnostics Company has filed 2 patents.
Where is BioBehavioral Diagnostics Company's headquarters?
BioBehavioral Diagnostics Company's headquarters is located at 2250 Hickory Road, Plymouth Meeting.
What is BioBehavioral Diagnostics Company's latest funding round?
BioBehavioral Diagnostics Company's latest funding round is Acquired.
How much did BioBehavioral Diagnostics Company raise?
BioBehavioral Diagnostics Company raised a total of $42.55M.
Who are the investors of BioBehavioral Diagnostics Company?
Investors of BioBehavioral Diagnostics Company include Pearson, Sevin Rosen Funds, Tullis Dickerson, Tullis Health Investors and Qualifying Therapeutic Discovery Project.
Who are BioBehavioral Diagnostics Company's competitors?
Competitors of BioBehavioral Diagnostics Company include Brain Tunnelgenix Technologies, INRange Systems, Acelity, Med-Tek, WaveTec Vision and 13 more.
You May Also Like
Medical devices for the treatment of severe gastrointestinal disorders
Biopharmaceutical products for the of spinal cord injuries and other central nervous system disorders.
Patton Medical Devices is a medical device company developing: I-Port Injection Port.The i-port® is a simple medication delivery device that relieves the hardships of daily injections for individuals with diabetes and other chronic conditions. Developed by KK Patton, a woman with diabetes, the i-port® aims to improve one's health and quality of life.
Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.
ES Vascular Ltd. developed first ever surgical stapling devices for endovascular surgery. These devices aim to transform vascular surgery by shortening procedural times, and by simplifying and potentially increasing the safety of the most common vascular interventions. The company is currently developing three product lines for open AAA, endovascular AAA and Femoro-Pop bypass procedures. Its first products are anticipated to enter the market in 2008.nCompany Snapshotn Started in 2000 in Israel by Prof. Shifrin together with group of engineers and leading vascular surgeons from the US and Europe;n Developed a ever vascular stapling technology for stapling synthetic grafts to the aortan Developed endovascular devices for EVAR and SFA procedures
Ligon Discovery is a drug discovery company built around the firm's primary technology platform, Small-Molecule Microarrays (SMMs).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.